Literature DB >> 33392104

Generation of a Genetically Modified Chimeric Plasmodium falciparum Parasite Expressing Plasmodium vivax Circumsporozoite Protein for Malaria Vaccine Development.

Yukiko Miyazaki1, Catherin Marin-Mogollon1, Takashi Imai1,2, António M Mendes3, Rianne van der Laak4, Angelika Sturm4, Fiona J A Geurten1, Shinya Miyazaki1, Severine Chevalley-Maurel1, Jai Ramesar1, Surendra K Kolli1, Hans Kroeze1, Roos van Schuijlenburg1, Ahmed M Salman5, Brandon K Wilder6, Arturo Reyes-Sandoval5, Koen J Dechering4, Miguel Prudêncio3, Chris J Janse1, Shahid M Khan1, Blandine Franke-Fayard1.   

Abstract

Chimeric rodent malaria parasites with the endogenous circumsporozoite protein (csp) gene replaced with csp from the human parasites Plasmodium falciparum (Pf) and P. vivax (Pv) are used in preclinical evaluation of CSP vaccines. Chimeric rodent parasites expressing PfCSP have also been assessed as whole sporozoite (WSP) vaccines. Comparable chimeric P. falciparum parasites expressing CSP of P. vivax could be used both for clinical evaluation of vaccines targeting PvCSP in controlled human P. falciparum infections and in WSP vaccines targeting P. vivax and P. falciparum. We generated chimeric P. falciparum parasites expressing both PfCSP and PvCSP. These Pf-PvCSP parasites produced sporozoite comparable to wild type P. falciparum parasites and expressed PfCSP and PvCSP on the sporozoite surface. Pf-PvCSP sporozoites infected human hepatocytes and induced antibodies to the repeats of both PfCSP and PvCSP after immunization of mice. These results support the use of Pf-PvCSP sporozoites in studies optimizing vaccines targeting PvCSP.
Copyright © 2020 Miyazaki, Marin-Mogollon, Imai, Mendes, van der Laak, Sturm, Geurten, Miyazaki, Chevalley-Maurel, Ramesar, Kolli, Kroeze, van Schuijlenburg, Salman, Wilder, Reyes-Sandoval, Dechering, Prudêncio, Janse, Khan and Franke-Fayard.

Entities:  

Keywords:  Plasmodium falciparum; Plasmodium vivax; chimeric parasites; circumsporozoite protein (CSP); malaria; vaccines

Mesh:

Substances:

Year:  2020        PMID: 33392104      PMCID: PMC7773900          DOI: 10.3389/fcimb.2020.591046

Source DB:  PubMed          Journal:  Front Cell Infect Microbiol        ISSN: 2235-2988            Impact factor:   5.293


  62 in total

1.  The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum.

Authors:  S Bowman; D Lawson; D Basham; D Brown; T Chillingworth; C M Churcher; A Craig; R M Davies; K Devlin; T Feltwell; S Gentles; R Gwilliam; N Hamlin; D Harris; S Holroyd; T Hornsby; P Horrocks; K Jagels; B Jassal; S Kyes; J McLean; S Moule; K Mungall; L Murphy; K Oliver; M A Quail; M A Rajandream; S Rutter; J Skelton; R Squares; S Squares; J E Sulston; S Whitehead; J R Woodward; C Newbold; B G Barrell
Journal:  Nature       Date:  1999-08-05       Impact factor: 49.962

2.  Controlled human malaria infection trials: How tandems of trust and control construct scientific knowledge.

Authors:  Else M Bijker; Robert W Sauerwein; Wiebe E Bijker
Journal:  Soc Stud Sci       Date:  2016-02       Impact factor: 3.885

Review 3.  Vaccines to Accelerate Malaria Elimination and Eventual Eradication.

Authors:  Julie Healer; Alan F Cowman; David C Kaslow; Ashley J Birkett
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

Review 4.  Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Authors:  Danielle I Stanisic; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

5.  High efficiency transfection of Plasmodium berghei facilitates novel selection procedures.

Authors:  Chris J Janse; Blandine Franke-Fayard; Gunnar R Mair; Jai Ramesar; Corinna Thiel; Sabine Engelmann; Kai Matuschewski; Geert Jan van Gemert; Robert W Sauerwein; Andrew P Waters
Journal:  Mol Biochem Parasitol       Date:  2005-10-07       Impact factor: 1.759

6.  Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.

Authors:  Lander Foquet; Cornelus C Hermsen; Geert-Jan van Gemert; Eva Van Braeckel; Karin E Weening; Robert Sauerwein; Philip Meuleman; Geert Leroux-Roels
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

7.  Implementation of RTS,S/AS01 Malaria Vaccine--The Need for Further Evidence.

Authors:  John Clemens; Vasee Moorthy
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

8.  Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax.

Authors:  Anjali Yadava; Norman C Waters
Journal:  PLoS Negl Trop Dis       Date:  2017-01-12

9.  Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.

Authors:  Erwan Atcheson; Karolis Bauza; Ahmed M Salman; Eduardo Alves; Joshua Blight; Martha Eva Viveros-Sandoval; Chris J Janse; Shahid M Khan; Adrian V S Hill; Arturo Reyes-Sandoval
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

10.  Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite.

Authors:  Alba Marina Gimenez; Luciana Chagas Lima; Katia Sanches Françoso; Priscila M A Denapoli; Raquel Panatieri; Daniel Y Bargieri; Jean-Michel Thiberge; Chiara Andolina; Francois Nosten; Laurent Renia; Ruth S Nussenzweig; Victor Nussenzweig; Rogerio Amino; Mauricio M Rodrigues; Irene S Soares
Journal:  Front Immunol       Date:  2017-10-11       Impact factor: 7.561

View more
  3 in total

1.  Live Vaccination with Blood-Stage Plasmodium yoelii 17XNL Prevents the Development of Experimental Cerebral Malaria.

Authors:  Takashi Imai; Ha Ngo-Thanh; Kazutomo Suzue; Aoi Shimo; Akihiro Nakamura; Yutaka Horiuchi; Hajime Hisaeda; Takashi Murakami
Journal:  Vaccines (Basel)       Date:  2022-05-11

2.  Structural basis of Plasmodium vivax inhibition by antibodies binding to the circumsporozoite protein repeats.

Authors:  Iga Kucharska; Lamia Hossain; Danton Ivanochko; Qiren Yang; John L Rubinstein; Régis Pomès; Jean-Philippe Julien
Journal:  Elife       Date:  2022-01-13       Impact factor: 8.140

3.  Sporozoite motility as a quantitative readout for anti-CSP antibody inhibition.

Authors:  C M de Korne; R van Schuijlenburg; J C Sijtsma; H M de Bes; E Baalbergen; S Azargoshasb; M N van Oosterom; M B B McCall; F W B van Leeuwen; M Roestenberg
Journal:  Sci Rep       Date:  2022-10-13       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.